Asia Pacific
Refine Search
Biotechnology
China is preparing to ease access to its capital markets for early-stage biotech companies, signaling what could be a turning of the tide after months of tightened restrictions that stalled initial public offerings. 20 June 2025
Pharmaceutical
Japanese drugmaker Mochida Pharmaceutical announced that Thien Thao Pharmaceutical Joint Stock Company, a partner of Meiji, has obtained approval to import and market Epadel S, a highly purified eicosapentaenoic acid (EPA) ethyl ester formulation sold by Mochida in Japan, for the treatment of hypertriglyceridemia in Vietnam. 20 June 2025
Biotechnology
Chinese biotech start-up BioTroy Therapeutics has raised over 200 million renminbi ($28 million) in series A financing to advance clinical trials for its experimental immunotherapy targeting CD3L1, a novel immune checkpoint aimed at tough-to-treat tumors. The company also plans to expand its early-stage pipeline and grow its Shanghai-based R&D team. 18 June 2025
Pharmaceutical
Japanese companies NEC Corporation and Chugai Pharmaceutical have entered a collaboration to conduct an experiment using AI to predict drug combinations that can possibly enhance the effectiveness of certain cancer treatments. 18 June 2025
Pharmaceutical
Japanese companies Axcelead and A2 Healthcare Corporation announced that they will enter a strategic partnership to promote pharmaceutical research and development in Japan.
Axcelead operates a global business built on two core pillars: drug discovery services and mRNA CDMO services. 18 June 2025
Biotechnology
South Korea’s clinical-stage biotech D&D Pharmatech saw its share leap as much as 30% as it revealed “remarkably positive” results on its metabolic dysfunction-associated steatohepatitis (MASH) candidate. 17 June 2025
Biotechnology
Shares of USA-based NextCure slumped 26% to $0.50 on Monday, after the company announced a strategic partnership with China-based Simcere Zaiming, subsidiary of Simcere Pharmaceutical Group Ltd to develop a therapy for the treatment of solid tumors. 17 June 2025
Biotechnology
Israel’s Teva Pharmaceutical Industries and Shanghai Fosun Pharmaceutical have entered a strategic partnership for the development of investigational TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy. 17 June 2025
Pharmaceutical
China’s National Medical Products Administration (NMPA) held a meeting last week to conduct the 2024 annual review of the quality management system (QMS) in vaccine regulation and pharmaceutical manufacturing inspection. 16 June 2025
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group. 13 June 2025
Biosimilars
South Korea’s biosimilar drug developer Samsung Bioepis today presented the long-term safety data of Epysqli (eculizumab; SB12), a biosimilar to AstraZeneca’s Soliris, in paroxysmal nocturnal hemoglobinuria (PNH) at the European Hematology Association (EHA) Congress 2025 held at Milan, Italy from June 12 to 15. 12 June 2025
Pharmaceutical
South Korean drugmaker JW Pharmaceutical has received regulatory approval in China for an injectable antibiotic made with its own synthesized active ingredient, marking a strategic expansion into the Asian market. 12 June 2025
Pharmaceutical
German science and technology firm Merck KGaA has moved a step closer to introducing a new therapy for tenosynovial giant cell tumor (TGCT) in China, with regulators accepting its marketing application and initiating a priority review for pimicotinib. 10 June 2025
Biosimilars
South Korea’s biosimilar drug developer Samsung Bioepis has announced that the company has entered into a license, development and commercialization agreement with Nipro Corporation for multiple biosimilar candidates including SB17, a ustekinumab biosimilar candidate, in Japan. 9 June 2025
Pharmaceutical
Canada-based Knight Therapeutics and the US subsidiary of Japan’s Sumitomo Pharma have entered into exclusive license and supply agreements to commercialize certain products. 9 June 2025
Biotechnology
Japan’s Otsuka today presented positive results from a pre-specified interim analysis of the Phase III VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of immunoglobulin A nephropathy (IgAN) in adults. 6 June 2025
Biotechnology
China-based Kelun-Biotech Biopharmaceutical announced the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital of the company post the placement. The shares were placed at HK$331.8 per share, raising net proceeds of around US$250 million. 6 June 2025
Biotechnology
The New Drug Application (NDA) for the combination of fruquintinib and sintilimab for locally advanced or metastatic renal cell carcinoma patients who have failed prior treatment with one tyrosine kinase inhibitor (TKI) has been accepted for review by the China National Medical Products Administration (NMPA). 5 June 2025
Biotechnology
US biopharma Cullinan Therapeutics has entered into an agreement with Genrix Bio for an all-indication, exclusive license to velinotamig, a BCMAxCD3 bispecific T-cell engager for everywhere outside Greater China. 5 June 2025
Pharmaceutical
China’s National Medical Products Administration approved its first domestically-developed nine-valent human papillomavirus (HPV) vaccine on Thursday. 5 June 2025
Biotechnology
In what is seen as an unusual decision, the UK’s National Institute for Health and Care Excellence (NICE) says it will convene a third appraisal committee meeting as part of its ongoing evaluation of Leqembi (lecanemab), the drug’s developers, Eisai and Biogen announced today. 6 March 2025
Biotechnology
French biopharmaceutical Osivax, which is developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, has announced the successful first close of its Series B financing, raising 10 million euros ($10.05 million) from new and existing investors. 6 March 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). 5 March 2025
Biosimilars
South Korea-based Celltrion today announced that the US Food and Drug Administration (FDA) has approved Stoboclo and Osenvelt (CT-P41, denosumab-bmwo), biosimilars referencing Amgen’s Prolia and Xgeva brands respectively for all indications of the reference products. 4 March 2025
Pharmaceutical
US clinical-stage pharma company Protagonist Therapeutics and Japan’s Takeda have announced positive top-line results for the Phase III VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV), a rare blood cancer, were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. 4 March 2025
Biotechnology
Japan’s Kyorin Pharmaceutical has entered into a global license agreement with Swiss pharma giant Novartis relating to KRP-M223 and its back-up compounds, which were discovered by the Tokyo-based firm. 4 March 2025
Pharmaceutical
USA/China-based SciClone Pharmaceuticals has entered into a license agreement with Japan’s Eisai for the latter’s fibroblast growth factor (FGF) receptor selective tyrosine kinase inhibitor tasurgratinib succinate (code named E7090). 3 March 2025
Biotechnology
The Therapeutic Goods Administration (TGA) of Australia has declined the approval of Leqembi (lecanemab) as a treatment for early Alzheimer’s disease (AD). 3 March 2025
Pharmaceutical
Japanese biopharma Nxera Pharma has announced two deals in a single day with partners that will commercialize its products in parts of Asia. 28 February 2025
Biotechnology
Sino American biotech BeiGene has announced financial results and corporate updates from the fourth quarter and full year 2024. The company’s shares rose 7.5% to $278.38 on the news. 28 February 2025
Pharmaceutical
South Korean vaccine maker SK bioscience today revealed that it has received prior notification from the Pan American Health Organization (PAHO), a specialized agency of the United Nations in charge of international health cooperation in the Americas, to supply its self-developed varicella (chickenpox) vaccine, SKYVaricella, to Latin America through 2027. 28 February 2025
Biotechnology
Duality Biologics, a Chinese biotech specializing in antibody-drug conjugates (ADCs), has opted not to move forward at this time with a plan to list on the Hong Kong Stock Exchange. 28 February 2025
Pharmaceutical
Privately-held BridGene Biosciences has announced a strategic collaboration and licensing agreement with Japan’s Takeda (TYO: 4502). The new deal expands on their initial 2021 partnership, valued at around $500 million, centered on chemoproteomics-based approaches to address "undruggable" targets. 26 February 2025
Biotechnology
US biotech major Amgen will invest about $200 million this year in its new technology center in southern India. 25 February 2025
Biotechnology
The Japanese Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Sarclisa (isatuximab), in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) based on data from the IMROZ Phase III study. 25 February 2025
Biosimilars
South Korean firm Celltrion announced that the European Commission (EC) has granted marketing authorization for Avtozma (CT-P47), a biosimilar referencing RoActemra (tocilizumab), which is marketed by Swiss pharma giant Roche. 25 February 2025
Pharmaceutical
In this episode, we’ll take a look at the role of Japanese pharmaceutical groups in the UK, with Jackie Davis, general manager at Astellas Pharma. 24 February 2025
Pharmaceutical
Mitsubishi Tanabe Pharma (MTPC) today announced that the European Medicines Agency (EMA) has accepted for review the marketing authorization application (MAA) for ND0612, an investigational treatment for motor fluctuations in Parkinson's disease (PD) on February 20. 24 February 2025
Pharmaceutical
Japanese drug major Shionogi announced that Jeil Pharmaceutical, its partner in South Korea, has obtained marketing approval from the domestic authorities for the gram-negative bacterial infection treatment Fetroja (cefiderocol). 24 February 2025
Biosimilars
South Korean biosimilars developer Celltrion late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), at the 20th European Crohn’s and Colitis Organisation (ECCO) Congress, showcasing the treatment’s effectiveness across a range of key clinical outcomes in inflammatory bowel disease (IBD). 21 February 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze